A detailed investigation was conducted into the key biological processes altered in trastuzumab/pertuzumab-resistant SK-BR-3 cells in order to understand the mechanisms underlying the resistance to anti-HER2 therapies in breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.